ArticleTherapeutic innovation & regulatory science2026
Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models.
Gloria Nnadwa AlhassanPubMed ↗Publisher ↗
No numbers read from the abstract.